Pure Bioscience, Inc (PURE)


Pure Bioscience, Inc. is a common stock listing on OTC Markets. The company develops and commercializes antimicrobial products designed to address pathogen control and hygiene needs in the United States and abroad. Its technology platform is built around silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent intended to provide residual protection and to be combined with other compounds. PURE Bioscience’s product lineup includes SDC-based disinfecting and sanitizing solutions such as PURE Hard Surface, PURE Control, PURE Multi-Purpose Hi-Foam Floor Cleaner Concentrate, PURE Multi-Purpose Floor Cleaner, and SILVERION, which is used as a raw material ingredient in personal care products. The company serves customers in food processing, food service, hospitality, healthcare, facility care, transportation, and personal care, and distributes its products through end users and third-party distributors. Incorporated in 1992, the company is based in El Cajon, California.


Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-PURE
$0.051
-15.6% Downside
Fair
Weak
0.0%
October 30, 2026
-3.8x
-1.4x
3.5x
8.438 M
13.926 M
43.5%
64.5%
-130.0
80.7%
Valuation • Fair Value

Pure Bioscience, Inc (OTC-PURE) Fair Value by Valuation Model

Compare the primary fair value estimate for Pure Bioscience, Inc (OTC-PURE) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$0.051

Estimated downside of 15.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$0.043

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$0.054

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Pure Bioscience, Inc (OTC-PURE) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Pure Bioscience, Inc (OTC-PURE)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

2.422 M

Current operating scale indicator.

Revenue Forecast

2.367 M

Forward revenue estimate.

EBITDA

-1.914 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Pure Bioscience, Inc (OTC-PURE) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Pure Bioscience, Inc (OTC-PURE)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-4.19

No elevated caution signal from this screen.

Altman Z-Score

-130.0

Lower score that deserves closer risk review.

FCF / Net Income

80.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Pure Bioscience, Inc (OTC-PURE). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Pure Bioscience, Inc (OTC-PURE)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

October 30, 2026

Days to Earnings

101

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Pure Bioscience, Inc (OTC-PURE), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Pure Bioscience, Inc (OTC-PURE) Stock Forecast & Technical Outlook

Review Pure Bioscience, Inc (OTC-PURE) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Pure Bioscience, Inc (OTC-PURE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Pure Bioscience, Inc (OTC-PURE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Pure Bioscience, Inc (OTC-PURE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Pure Bioscience, Inc (OTC-PURE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Pure Bioscience, Inc (OTC-PURE) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Pure Bioscience, Inc (OTC-PURE)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Pure Bioscience, Inc (OTC-PURE) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ Fast Investor Answers

Pure Bioscience, Inc (OTC-PURE) Stock FAQ

Quick answers about Pure Bioscience, Inc (OTC-PURE) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$0.051
Estimated downside 15.6%
Valuation Rating
Overvalued
Estimated downside of 15.6%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for Pure Bioscience, Inc (OTC-PURE) is $0.051. This implies an estimated downside of 15.6% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 15.6% versus the current market price.

An analyst price target for Pure Bioscience, Inc (OTC-PURE) is not currently available in the latest data file.

The current financial health read for Pure Bioscience, Inc (OTC-PURE) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Pure Bioscience, Inc (OTC-PURE) is October 30, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Pure Bioscience, Inc (OTC-PURE) is -3.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Pure Bioscience, Inc is 8.438 M.

The current enterprise value listed for Pure Bioscience, Inc is 13.926 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Pure Bioscience, Inc is OTC-PURE, and the stock is listed on OTC Markets.

Pure Bioscience, Inc (OTC-PURE) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Pure Bioscience, Inc is 43.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Pure Bioscience, Inc is 64.5%. Free float helps investors understand how much of the share base is available for public trading.